FDA Determines Regulatory Review Period for ULTIVA Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for ULTIVA, a human drug product, in response to a patent extension application submitted to the Commissioner of Patents and Trademarks, Department of Commerce.